TITLE

There's Gold in Them There Pills

AUTHOR(S)
Ognibene, Peter J.
PUB. DATE
April 1973
SOURCE
New Republic;4/21/73, Vol. 168 Issue 16, p13
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Focuses on growing abuse of methaqualone, a sedative-hypnotic often prescribed for insomnia, in the U.S. Plea of the Food and Drug Administration to study the problem; Statement that a few pills of methaqualone makes one drunk and higher doses can result in unconsciousness, coma or even death; View that drug firms have been building a safe image for methaqualone as a nonaddictive downer in their advertising; Statement that if the administration takes the advice of its Bureau of Narcotics and Dangerous Drugs and put the drug under the strict controls of Schedule II, its destructive impact could be appreciably lessened.
ACCESSION #
10152054

 

Related Articles

  • buzz: FEWER NEEDLES FOR DIABETICS.  // Better Homes & Gardens;Apr2006, Vol. 84 Issue 4, p268 

    The article reports that the U.S. Food and Drug Administration has approved Exubera, a powdered inhaled form of insulin.

  • FDA revives compounding advisory committee. Traynor, Kate // American Journal of Health-System Pharmacy;4/15/2015, Vol. 72 Issue 8, p598 

    The article offers information on the revival of list of drugs by the U.S. Food and Drug Administration (FDA)'s Pharmacy Compounding Advisory Committee that may not be used for compounding. Topics discussed include FDA regulations for compounded products, the Drug Quality and Security Act (DQSA)...

  • Guidance for Industry on Incorporation of Physical-Chemical Identifiers Into Solid Oral Dosage Form Drug Products for Anticounterfeiting; Availability. Kux, Leslie // Federal Register (National Archives & Records Service, Office of;10/12/2011, Vol. 76 Issue 197, p63304 

    The article announces the availability of the "Incorporation of Physical- Chemical Identifiers Into Solid Oral Dosage Form Drug Products for Anticounterfeiting" guidance from the U.S. Food and Drug Administration (FDA), which provides recommendations on design considerations for incorporating...

  • Guidance for Industry on Incorporation of Physical-Chemical Identifiers Into Solid Oral Dosage Form Drug Products for Anticounterfeiting; Availability. Kux, Leslie; Almanza, Alfred V. // Federal Register (National Archives & Records Service, Office of;10/12/2011, Vol. 76 Issue 197, p63305 

    The article announces the availability of the "Incorporation of Physical- Chemical Identifiers Into Solid Oral Dosage Form Drug Products for Anticounterfeiting" guidance from the U.S. Food and Drug Administration (FDA), which provides recommendations on design considerations for incorporating...

  • Current FDA-Related Drug Information. Baker, Danial E. // Hospital Pharmacy;Feb2006, Vol. 41 Issue 2, p174 

    The article provides information on new drugs, indications, dosage forms and safety-related changes in labeling or use, which were approved by the U.S. Food and Drug Administration in 2005. IPlex is developed for the treatment of growth failure in children with severe primary IGF-1 deficiency....

  • The Drug Quality and Security Act. Gabay, Michael // Hospital Pharmacy;Jul/Aug2014, Vol. 49 Issue 7, p615 

    The article offers information on the U.S. Drug Quality and Security Act which was signed into law by U.S. President Barack Obama in November 2013. It mentions the current changes in the law include the change in the Section 503A of the Food, Drug, and Cosmetics Act (FDCA) related to the...

  • COLPOUNDING & the Practicing Urologist.  // Urology Times;May2012 Supplement, p1 

    An interview with Sheldon Bradshaw, a former chief counsel of the U.S. Food and Drug Administration (FDA), on pharmacy compounding is presented. Bradshaw mentions the recognition by FDA of the importance of conventional pharmacy compounding. He explains that compounded drugs should only be used...

  • Safety woes. Carlson, Joe // Modern Healthcare;4/15/2013, Vol. 43 Issue 15, p4 

    The article reports that the U.S. Food and Drug Administration (FDA) found deficiencies at 31 compounding factories across the nation. An aggressive inspection program conducted by FDA at higher-risk facilities that produce sterile compounded drugs found air filters marked with dark-amber stains...

  • Taking the risk. Lee, Jaimy; Barr, Paul // Modern Healthcare;10/15/2012, Vol. 42 Issue 42, p6 

    The article reports on the use of compounding pharmacies for hard-to-obtain drugs by U.S. hospitals despite an outbreak of a deadly meningitis caused by a compounding facility. An estimated 182 people had contracted fungal meningitis after receiving contaminated steroid injections from the New...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics